|
| Monday, December 2, 2024 |
|
|
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia |
| China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia more info >> |
|
|
康哲藥業獲得治療痛風及高尿酸血症的1類新藥獨家商業化權利 |
| 康哲藥業控股有限公司（以下簡稱「康哲藥業」）欣然宣佈，於2024年12月2日，通過其全資附屬公司與杭州新元素藥業有限公司（以下稱「新元素藥業」，曾用名「江蘇新元素醫藥科技有限公司」）就治療痛風及高尿酸血症的1類新藥ABP-671（「產品」）簽訂獨家商業化協議（「協議」）。 more info >> |
|
|
康哲药业获得治疗痛风及高尿酸血症的1类新药独家商业化权利 |
| 康哲药业控股有限公司（以下简称"康哲药业"）欣然宣布，于2024年12月2日，通过其全资附属公司与杭州新元素药业有限公司（以下称"新元素药业"，曾用名"江苏新元素医药科技有限公司"）就治疗痛风及高尿酸血症的1类新药ABP-671（"产品"）签订独家商业化协议（"协议"）。 more info >> |
|
| Monday, October 21, 2024 |
|
|
康哲药业入选2024年度“中国医药上市公司ESG竞争力”系列榜单 |
| 近日，E药经理人联合中国领先的企业社会责任独立咨询机构发布2024年度“中国医药上市公司ESG竞争力”系列榜单，旨在表彰在ESG管理各方面具有标杆作用的中国医药企业。康哲药业凭借在可持续发展、低碳行动方面的不断努力，连续三年入选“中国医药上市公司ESG竞争力TOP20（中盘股）”榜单，并入选首届“中国医药上市公司低碳先锋TOP10”榜单。 more info >> |
|
|
China Medical System: First Ruxolitinib Cream's Prescriptions for Vitiligo Issued in the Greater Bay Area |
| China Medical System Holdings Limited (the "Group" or "CMS") is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. more info >> |
|
| Friday, October 18, 2024 |
|
|
康哲药业：芦可替尼乳膏（白癜风）大湾区首批处方落地 |
| 康哲药业控股有限公司（“康哲药业”）欣然宣布，磷酸芦可替尼乳膏（“芦可替尼乳膏”或“产品”）在中山陈星海中西医结合医院、佛山复星禅诚医院、以及东莞松山湖东华医院为符合条件的白癜风患者开出大湾区首批处方。 more info >> |
|
| Tuesday, September 24, 2024 |
|
|
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
|
China Medical System: New Drug Application for Vitiligo Indication of Ruxolitinib Phosphate Cream Accepted in China |
| China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group" or "CMS") is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the "ruxolitinib cream" or the "Product") has been accepted by the National Medical Products Administration of China (NMPA). more info >> |
|
|
康哲药业：磷酸芦可替尼乳膏（白癜风）中国上市许可申请已获受理 |
| 康哲药业控股有限公司（“本公司”，连同其附属公司统称为“本集团”或“康哲药业”）欣然宣布，磷酸芦可替尼乳膏（“芦可替尼乳膏”或“产品”）（白癜风适应症）新药上市许可申请（NDA）已于2024年9月24日获得中国国家药品监督管理局（NMPA）受理。 more info >> |
|
| Friday, August 16, 2024 |
|
|
康哲藥業（00867）發佈2024年中期業績：營業額和利潤環比均穩步提升 |
| 2024年8月15日，康哲藥業發佈2024年中期業績公告，整體營業額和期間利潤環比去年下半年穩步提升。2024年上半年實現營收36.11億元，同比下降21.7%，環比增長6.1%；若全按藥品銷售收入計算營收42.88億元，同比下降22.6%，環比增長8.9%；其中，非國採獨家產品及創新產品合計銷售收入為人民幣24.05億元，佔全按藥品銷售收入計算營業額的56.1%。實現淨利潤9.03億元，同比下降52.8%，環比大幅增長92.8%。 more info >> |
|
|
|
|
